Co-Authors
This is a "connection" page, showing publications co-authored by Ilad Alavi Darazam and Shervin Shokouhi.
Connection Strength
2.156
-
Resolution of Chest X-Ray Opacities in Patients with Ventilator-associated Pneumonia. Infect Disord Drug Targets. 2018; 18(1):23-28.
Score: 0.374
-
Community-acquired methicillin-resistant Staphylococcus aureus carriage rate and antimicrobial susceptibility in a tertiary center, Iran. J Res Med Sci. 2017; 22:71.
Score: 0.361
-
Umifenovir in hospitalized moderate to severe COVID-19 patients: A randomized clinical trial. Int Immunopharmacol. 2021 Oct; 99:107969.
Score: 0.239
-
An investigation into the beneficial effects of high-dose interferon beta 1-a, compared to low-dose interferon beta 1-a in severe COVID-19: The COVIFERON II randomized controlled trial. Int Immunopharmacol. 2021 Oct; 99:107916.
Score: 0.238
-
An investigation into the beneficial effects of high-dose interferon beta 1-a, compared to low-dose interferon beta 1-a (the base therapeutic regimen) in moderate to severe COVID-19: A structured summary of a study protocol for a randomized controlled l trial. Trials. 2020 Oct 26; 21(1):880.
Score: 0.227
-
Diagnostic Value of the Leukocyte Esterase Test for Early Detection of Pleocytosis in Cerebrospinal Fluid of Patients with Suspected Acute Bacterial Meningitis. Infect Disord Drug Targets. 2018; 18(1):29-34.
Score: 0.187
-
Urine Vancomycin Level as a Method for Drug Monitoring in Patients With Normal and Decreased Kidney Function. Iran J Kidney Dis. 2017 Oct; 11(5):367-370.
Score: 0.184
-
Diagnostic Yield of a Direct Quantitative Smear of Lower Respiratory Tract Secretions in Patients with Suspected Pneumonia Compared to a Semi-quantitative Culture. Tanaffos. 2017; 16(1):9-12.
Score: 0.175
-
Effectiveness of Interferon Beta 1a, compared to Interferon Beta 1b and the usual therapeutic regimen to treat adults with moderate to severe COVID-19: structured summary of a study protocol for a randomized controlled trial. Trials. 2020 Jun 03; 21(1):473.
Score: 0.111
-
Evaluation of the prophylactic effect of hydroxychloroquine on people in close-contact with patients with COVID-19. Pulm Pharmacol Ther. 2021 10; 70:102069.
Score: 0.060